Is VRTX or VTGN more undervalued in 2026?

CirclFi compares Vertex Pharmaceuticals Incorpor (VRTX) and VistaGen Therapeutics, Inc. (VTGN) using 13 institutional-grade valuation models. VRTX has a Quality of Company score of 10.0/10 while VTGN scores 6.0/10.

Which is a better buy — VRTX or VTGN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VRTX and VTGN valuations compare?

VRTX at $447.54 and VTGN at $0.63 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VRTX vs VTGN Valuation Comparison 2026 — Intrinsic Value Analysis

VRTX

Pharmaceutical Preparations

Vertex Pharmaceuticals Incorpor

Quality

10.0

out of 10

Value Trap

SAFE

Price

$447.54

Last close

Models

13/13

Active

VTGN

Pharmaceutical Preparations

VistaGen Therapeutics, Inc.

Quality

6.0

out of 10

Value Trap

LOW

Price

$0.63

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	VRTX Fair Value	VRTX Upside	VTGN Fair Value	VTGN Upside
Bayesian DCF	Intrinsic	$272.64	-39.1%	$0.82	+30.3%
Earnings Power Value	Intrinsic	$154.03	-65.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$44.19	-90.1%	$2.62	+315.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VRTX vs VTGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VRTX vs VTGN — Which Stock Is More Undervalued?

VRTX scores higher with a 10.0/10 quality rating vs VTGN's 6.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vertex Pharmaceuticals Incorpor (VRTX) and VistaGen Therapeutics, Inc. (VTGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VRTX currently trades at $447.54 with a QOC of 10.0/10, while VTGN trades at $0.63 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).